ArticleResearch and practice in thrombosis and haemostasis2017
Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.
Article in Research and practice in thrombosis and haemostasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Mendelian randomization identifies causal effects of phospholipids on portal vein thrombosis risk: FADS1/2-mediated pathways and their potential as diagnostic biomarkers.Nutrition & metabolism · 2026Article
- Selective targeting of coagulation factor X Gla domain by negatively charged gold nanoparticles: a novel method for controlled antithrombotic therapy.Materials today. Bio · 2025Article
- VITT Pathophysiology: An Update.Vaccines · 2025Review
- Independent Risk Factors of Non-Resolution Mural Thrombus in ST-Segment Elevation Myocardial Infarction Patients with Left Ventricular Aneurysms.Reviews in cardiovascular medicine · 2025Article
- Beyond platelet activation: dysregulated lipid metabolism in defining risk and pathophysiology of VITT.Research and practice in thrombosis and haemostasis · 2025Article
- Identification of oxylipins and lipid mediators in pulmonary embolism.Lipids in health and disease · 2024Article
- Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism.Haematologica · 2024Article
- The Association of High Lipoprotein(a) Concentration and Risk of Ischaemic Stroke in Atrial Fibrillation Patients.International journal of general medicine · 2024Article
- L-Palmitoylcarnitine potentiates plasmin and tPA to inhibit thrombosis.Natural products and bioprospecting · 2023Article
- Epidemic trends of dyslipidemia in young adults: a real-world study including more than 20,000 samples.Lipids in health and disease · 2023Observational
- Association between lipoprotein(a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study.Lipids in health and disease · 2022Article
- Relationship between lipoproteins, thrombosis, and atrial fibrillation.Cardiovascular research · 2022Review
- Association between Lipoprotein Subfractions, Hemostatic Potentials, and Coronary Atherosclerosis.Disease markers · 2022Article
- Elucidation of the Mechanisms and Effective Substances of Paeoniae Radix Rubra Against Toxic Heat and Blood Stasis Syndrome With a Stage-Oriented Strategy.Frontiers in pharmacology · 2022Article
- Dissecting lipid metabolism alterations in SARS-CoV-2.Progress in lipid research · 2021Review
- Serum amyloid A4 is a procoagulant apolipoprotein that it is elevated in venous thrombosis patients.Research and practice in thrombosis and haemostasis · 2020Article
- Structural basis of CaeLife · 2019Article
- Article
- Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.Research and practice in thrombosis and haemostasis · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Different minor abundance plasma lipids significantly influence thrombin generation in vitro and significant differences in such lipids are linked to risk for venous thrombosis. Some plasma sphingolipids including glucosylceramide, lyso-sulfatide and sphingosine have anticoagulant properties whereas, conversely, some plasma phospholipid derivatives, including certain lyso-phospholipids and ethanolamides, have procoagulant properties. Plasma metabolite profiling of venous thrombosis patients showed association of venous thrombosis with decreased plasma long-chain acylcarntines, leading to discovery of their anticoagulant activity as inhibitors of factor Xa. Inhibition of factor Xa by acylcarnitines does not require the protein's Gla-domain, emphasizing an expanded framework for the paradigm for lipid-clotting factor interactions. Overall, whether by genetics or environment, alterations in the dynamics of lipid metabolism linked to an altered lipidome may contribute to regulation of blood coagulation because imbalances between physiologic procoagulant and anticoagulant lipids may contribute to excessive thrombin generation that augments risk for thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.